AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16810765 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 220
Study 12762431 — intervention group
Group type: EXPERIMENTAL
Intervention: Eradication treatment (ET group) with Lansoprazol 30 mg/day for three months
Number of subjects: 27
Study 12762431 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic treatment (ST group) with Lansoprazol 30 mg/day for three months
Number of subjects: 27
Study 10690445 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance exercise (PRE) for 52 weeks, three one hour sessions a week
Number of subjects: 44
Study 10690445 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal lifestyle)
Number of subjects: 44
Study 10690445 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic leg strength
Number of subjects: 44
Study 10175551 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath-actuated inhaler (BAI)
Number of subjects: 301
Study 10175551 — intervention group
Group type: COMPARATOR
Intervention: Manually operated metered dose inhaler (MDI)
Number of subjects: 301
Study 8228122 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. imipenem/cilastatin
Number of subjects: 100
Study 8228122 — intervention group
Group type: COMPARATOR
Intervention: Dextrose-saline (control)
Number of subjects: 100
Study 8228122 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency sclerotherapy
Number of subjects: 100
Study 8228122 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective sclerotherapy
Number of subjects: 100
Study 3767127 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol (4.0 mg)
Number of subjects: 20
Study 3767127 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline (5.0 mg)
Number of subjects: 20
Study 30583332 — intervention group
Group type: EXPERIMENTAL
Intervention: i-gelTM
Number of subjects: 101
Study 30583332 — intervention group
Group type: EXPERIMENTAL
Intervention: AuraOnceTM
Number of subjects: 101
Study 24673362 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence intervention
Number of subjects: 180
Study 24673362 — intervention group
Group type: COMPARATOR
Intervention: Nonadherent pattern
Number of subjects: 180
Study 25091820 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (160mg/day) plus citalopram (20mg/day)
Number of subjects: 10
Study 25091820 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus citalopram (20mg/day)
Number of subjects: 10
Study 22384973 — intervention group
Group type: EXPERIMENTAL
Intervention: YINYI stent (polymer-free paclitaxel-eluting stent)
Number of subjects: 167
Study 22384973 — intervention group
Group type: COMPARATOR
Intervention: EXCEL stent (biodegradable polymer-based rapamycin-eluting stent)
Number of subjects: 167
Study 20167066 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-symbolic magnitude comparison task
Number of subjects: 65
Study 20167066 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal counting knowledge and simple arithmetic tests
Number of subjects: 65
Study 18663300 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoridated dentifrice (twice per day)
Number of subjects: 29
Study 18083023 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant 750mg
Number of subjects: 60
Study 18083023 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen 20mg
Number of subjects: 60
Study 15363566 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5mg daily (D/D group)
Number of subjects: 0
Study 15363566 — intervention group
Group type: COMPARATOR
Intervention: Placebo followed by Dutasteride 0.5mg daily (P/D group)
Number of subjects: 0
Study 11605561 — intervention group
Group type: EXPERIMENTAL
Intervention: Task instructions emphasizing position
Number of subjects: 0
Study 11605561 — intervention group
Group type: COMPARATOR
Intervention: Task instructions emphasizing colour
Number of subjects: 0
Study 11605561 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimuli similar to those used by van der Heijden et al.
Number of subjects: 0
Study 9390608 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 2.0 mg and glycopyrrolate 0.4 mg intravenously (Group A)
Number of subjects: 162
Study 9390608 — intervention group
Group type: COMPARATOR
Intervention: No drugs to facilitate antagonism of blockade (Group B)
Number of subjects: 162
Study 7808034 — intervention group
Group type: EXPERIMENTAL
Intervention: 13‐cis retinoic acid
Number of subjects: 0
Study 7808034 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxy phenyl retinamide
Number of subjects: 0
Study 7808034 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard response criteria
Number of subjects: 0
Study 7808034 — intervention group
Group type: EXPERIMENTAL
Intervention: Response rates as low as 5%
Number of subjects: 0
Study 7808034 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival
Number of subjects: 0
Study 3662385 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 0
Study 3662385 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30842038 — intervention group
Group type: EXPERIMENTAL
Intervention: nal-IRI + 5-FU/LV
Number of subjects: 417
Study 30842038 — intervention group
Group type: COMPARATOR
Intervention: 5-FU/LV
Number of subjects: 417
Study 30113876 — intervention group
Group type: EXPERIMENTAL
Intervention: 256-Hz tuning fork sensation groups (TFSG)
Number of subjects: 36
Study 26874927 — intervention group
Group type: EXPERIMENTAL
Intervention: Pay-for-performance (P4P) intervention
Number of subjects: 6848
Study 25277549 — intervention group
Group type: EXPERIMENTAL
Intervention: Endobronchial valve (EBV) therapy
Number of subjects: 0
Study 25277549 — intervention group
Group type: COMPARATOR
Intervention: Medical management (control)
Number of subjects: 0
Study 22381771 — intervention group
Group type: EXPERIMENTAL
Intervention: TMZ-RT group (60 Gy radiotherapy with concurrent temozolomide treatment)
Number of subjects: 96
Study 22381771 — intervention group
Group type: COMPARATOR
Intervention: VM-RT group (60 Gy radiotherapy with concurrent VM-26 plus Me-CCNU treatments)
Number of subjects: 96
Study 20155520 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial intervention in dementia home care
Number of subjects: 0
Study 20155520 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary case management
Number of subjects: 0
Study 20155520 — intervention group
Group type: EXPERIMENTAL
Intervention: Respite care
Number of subjects: 0
Study 17332104 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinded outcome assessment
Number of subjects: 32
Study 17332104 — intervention group
Group type: COMPARATOR
Intervention: Unblinded outcome assessment
Number of subjects: 32
Study 17332104 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinded outcome assessment (dichotomous outcomes)
Number of subjects: 32
Study 17332104 — intervention group
Group type: COMPARATOR
Intervention: Unblinded outcome assessment (dichotomous outcomes)
Number of subjects: 32
Study 17332104 — intervention group
Group type: COMPARATOR
Intervention: Unblinded to blinded outcomes assessment ratio
Number of subjects: 32
Study 16277142 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based behavioral lifestyle modification program
Number of subjects: 57
Study 16277142 — intervention group
Group type: COMPARATOR
Intervention: Internet-based health education program (control)
Number of subjects: 57
Study 12443672 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral killed cholera vaccine
Number of subjects: 0
Study 12443672 — intervention group
Group type: COMPARATOR
Intervention: Natural infections with enterotoxigenic Escherichia coli
Number of subjects: 0
Study 10442154 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplement (20,000 IU beta-carotene, 400 IU vitamin E, 500 mg vitamin C, 100 micrograms selenium, 30 mg zinc)
Number of subjects: 30
Study 10442154 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplement
Number of subjects: 30
Study 10442154 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 8546287 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion (total dose 860 mg, range 540‐1520 mg)
Number of subjects: 30
Study 8546287 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane (median end‐expiratory concentration 0.6%, range 0.5‐0.8)
Number of subjects: 30
Study 2692675 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA
Number of subjects: 10
Study 2692675 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 820703 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 35
Study 820703 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 35
Study 30922964 — intervention group
Group type: EXPERIMENTAL
Intervention: DPP-4 inhibitors (DPP-4i)
Number of subjects: 0
Study 30922964 — intervention group
Group type: COMPARATOR
Intervention: α-glucosidase inhibitor (acarbose)
Number of subjects: 0
Study 27856001 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral high-fat polyunsaturated fatty acid (HF-PUFA) blend of fish oil and safflower oil
Number of subjects: 32
Study 27856001 — intervention group
Group type: COMPARATOR
Intervention: Standard nutritional therapy (control)
Number of subjects: 32
Study 25523240 — intervention group
Group type: EXPERIMENTAL
Intervention: Training towards painful faces
Number of subjects: 0
Study 25523240 — intervention group
Group type: EXPERIMENTAL
Intervention: Training away from painful stimuli (both faces and words)
Number of subjects: 0
Study 25523240 — intervention group
Group type: EXPERIMENTAL
Intervention: Training on pain-related words
Number of subjects: 0
Study 25523240 — intervention group
Group type: EXPERIMENTAL
Intervention: Training on painful faces
Number of subjects: 0
Study 25523240 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 0
Study 24866715 — intervention group
Group type: EXPERIMENTAL
Intervention: Siblings' survival calendar (SSC)
Number of subjects: 0
Study 24866715 — intervention group
Group type: COMPARATOR
Intervention: Demographic and Health Surveys (DHS) questionnaire
Number of subjects: 0
Study 22878126 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiation with capecitabine and cisplatin with or without cetuximab
Number of subjects: 50
Study 20025685 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus-based therapy
Number of subjects: 76
Study 20025685 — intervention group
Group type: COMPARATOR
Intervention: Neoral cyclosporine-based therapy
Number of subjects: 76
Study 17293709 — intervention group
Group type: EXPERIMENTAL
Intervention: quetiapine 600 mg/day
Number of subjects: 542
Study 17293709 — intervention group
Group type: EXPERIMENTAL
Intervention: quetiapine 300 mg/day
Number of subjects: 542
Study 17293709 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 542
Study 15365065 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin alone
Number of subjects: 89
Study 15365065 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin and tamoxifen
Number of subjects: 89
Study 15365065 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen alone
Number of subjects: 89
Study 15365065 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin alone (1 year after cessation)
Number of subjects: 89
Study 15264726 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.5 mg x kg(‐1) pre‐induction bolus followed by intravenous infusion of ketamine 0.5 mg x kg(‐1) x h(‐1) for 72 hours
Number of subjects: 45
Study 15264726 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline) as pre‐induction bolus followed by normal saline infusion for 72 hours
Number of subjects: 45
Study 11713926 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg
Number of subjects: 16
Study 11713926 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 9407701 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone (7.5 mg)
Number of subjects: 0
Study 9407701 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (10 mg)
Number of subjects: 0
Study 9407701 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8428407 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary red cell morphology assessment by Observer 1 using phase-contrast microscopy
Number of subjects: 62
Study 8428407 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary red cell morphology assessment by Observer 2 using phase-contrast microscopy and Nomarski differential interference microscopy
Number of subjects: 62
Study 8428407 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Nomarski differential interference microscopy to phase-contrast microscopy
Number of subjects: 62
Study 2890398 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial surfactant (ALEC)
Number of subjects: 328
Study 2890398 — intervention group
Group type: COMPARATOR
Intervention: 1 ml saline (control)
Number of subjects: 328
Study 31903494 — intervention group
Group type: EXPERIMENTAL
Intervention: BTI + Airman's Guide to Remaining Tobacco Free (AG)
Number of subjects: 2999
Study 31903494 — intervention group
Group type: EXPERIMENTAL
Intervention: Airman's Guide to Remaining Tobacco Free (AG)
Number of subjects: 2999
Study 31903494 — intervention group
Group type: COMPARATOR
Intervention: Standard smoking cessation intervention
Number of subjects: 2999
Study 29668302 — intervention group
Group type: EXPERIMENTAL
Intervention: Upfront neck dissection (UFND)
Number of subjects: 63
Study 29668302 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypopharyngeal cancer and carcinoma of unknown primary
Number of subjects: 63
Study 29668302 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 63
Study 27229707 — intervention group
Group type: COMPARATOR
Intervention: IVB 1.25 mg
Number of subjects: 45
Study 27229707 — intervention group
Group type: EXPERIMENTAL
Intervention: IVB 1.25 mg with STA 40 mg
Number of subjects: 45
Study 26271061 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon-expandable valve
Number of subjects: 241
Study 26271061 — intervention group
Group type: COMPARATOR
Intervention: Self-expandable valve
Number of subjects: 241
Study 24111757 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 0
Study 24111757 — intervention group
Group type: EXPERIMENTAL
Intervention: Strict glycemic control
Number of subjects: 0
Study 24111757 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy in critically ill patients
Number of subjects: 0
Study 24111757 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 20855136 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 ml of a fat emulsion (Calogen(®)) 3 times daily, providing 420 kcal
Number of subjects: 71
Study 20855136 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 71
Study 18332475 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (LET)
Number of subjects: 2383
Study 18332475 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLAC)
Number of subjects: 2383
Study 16580960 — intervention group
Group type: EXPERIMENTAL
Intervention: SPECT‐35%
Number of subjects: 10
Study 16580960 — intervention group
Group type: EXPERIMENTAL
Intervention: Planar RNA
Number of subjects: 10
Study 16580960 — intervention group
Group type: EXPERIMENTAL
Intervention: SPECT‐QBS
Number of subjects: 10
Study 12664054 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood cardioplegia
Number of subjects: 14
Study 12664054 — intervention group
Group type: COMPARATOR
Intervention: Crystalloid cardioplegia
Number of subjects: 14
Study 10858989 — intervention group
Group type: EXPERIMENTAL
Intervention: IgE antibody titers to ovalbumin
Number of subjects: 21
Study 10858989 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentration of pepsin-treated ovomucoid for 50% RAST inhibition
Number of subjects: 21
Study 10858989 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentration of chymotrypsin-treated ovomucoid for 50% RAST inhibition
Number of subjects: 21
Study 10858989 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentration of trypsin-treated ovomucoid for 50% RAST inhibition
Number of subjects: 21
Study 8790077 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin therapy
Number of subjects: 83
Study 8790077 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin therapy
Number of subjects: 83
Study 8790077 — intervention group
Group type: COMPARATOR
Intervention: Mild stroke
Number of subjects: 83
Study 8790077 — intervention group
Group type: COMPARATOR
Intervention: Moderate stroke
Number of subjects: 83
Study 8790077 — intervention group
Group type: COMPARATOR
Intervention: Major stroke
Number of subjects: 83
Study 1592884 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 1592884 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 micrograms/kg oral GHRP
Number of subjects: 10
Study 1592884 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms/kg oral GHRP
Number of subjects: 10
Study 1592884 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 micrograms/kg oral GHRP
Number of subjects: 10
Study 1592884 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 microgram/kg iv GHRP
Number of subjects: 10
Study 6205052 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 per cent chlorhexidine-detergent solution
Number of subjects: 3602
Study 6205052 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine cord care with 4 per cent chlorhexidine-detergent solution
Number of subjects: 3602
Study 31376949 — intervention group
Group type: EXPERIMENTAL
Intervention: SURPAS
Number of subjects: 1006
Study 31376949 — intervention group
Group type: COMPARATOR
Intervention: ACS-SRC
Number of subjects: 1006
Study 30311348 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-chain omega-3 polyunsaturated fatty acid (LCn3PUFA) intake
Number of subjects: 351
Study 28196620 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person education
Number of subjects: 514
Study 28196620 — intervention group
Group type: EXPERIMENTAL
Intervention: Online education
Number of subjects: 514
Study 25543127 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI)
Number of subjects: 304
Study 25543127 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 304
Study 24576788 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients with diabetic cardiomyopathy
Number of subjects: 2042
Study 24576788 — intervention group
Group type: COMPARATOR
Intervention: Diabetic patients
Number of subjects: 2042
Study 22473163 — intervention group
Group type: COMPARATOR
Intervention: CAPOX (capecitabine/oxaliplatin)
Number of subjects: 165
Study 19948278 — intervention group
Group type: EXPERIMENTAL
Intervention: Verteporfin photodynamic therapy (VPDT)
Number of subjects: 0
Study 19948278 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 0
Study 17321425 — intervention group
Group type: EXPERIMENTAL
Intervention: PACE+ intervention (behavioral intervention targeting physical activity, sedentary, and dietary behaviors)
Number of subjects: 657
Study 17321425 — intervention group
Group type: EXPERIMENTAL
Intervention: PACE intervention (for girls experiencing weight reduction or maintenance)
Number of subjects: 657
Study 15346704 — intervention group
Group type: EXPERIMENTAL
Intervention: Regrow 120 mg
Number of subjects: 75
Study 15346704 — intervention group
Group type: EXPERIMENTAL
Intervention: Regrow 240 mg
Number of subjects: 75
Study 15346704 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 75
Study 11870795 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed KTP laser treatment with aqueous gel
Number of subjects: 19
Study 11870795 — intervention group
Group type: COMPARATOR
Intervention: Pulsed KTP laser treatment without aqueous gel
Number of subjects: 19
Study 10444727 — intervention group
Group type: EXPERIMENTAL
Intervention: Recalled women (n=252)
Number of subjects: 252
Study 10444727 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=1104)
Number of subjects: 252
Study 8861460 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g of uncooked cornstarch as part of the 21:00 evening snack
Number of subjects: 51
Study 8861460 — intervention group
Group type: COMPARATOR
Intervention: Standard snack of equivalent carbohydrate content
Number of subjects: 51
Study 2177746 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg Org 2766 (synthetic analog of ACTH 4‐9)/day for 4 weeks
Number of subjects: 14
Study 2177746 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 431837 — intervention group
Group type: EXPERIMENTAL
Intervention: gamma‐ethylester of glutamic acid
Number of subjects: 45
Study 431837 — intervention group
Group type: EXPERIMENTAL
Intervention: arginine
Number of subjects: 45
Study 431837 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 45
Study 6343148 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral etretinate (Tigason)
Number of subjects: 40
Study 6343148 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 31174570 — intervention group
Group type: EXPERIMENTAL
Intervention: RAS gait training
Number of subjects: 50
Study 29981192 — intervention group
Group type: EXPERIMENTAL
Intervention: Football simulated fatigue (90 minutes of the modified Loughborough Intermittent Shuttle Test)
Number of subjects: 15
Study 29981192 — intervention group
Group type: COMPARATOR
Intervention: Seated rest (control condition)
Number of subjects: 15
Study 27088480 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic intervention
Number of subjects: 36
Study 27088480 — intervention group
Group type: COMPARATOR
Intervention: Conventional intervention
Number of subjects: 36
Study 25166761 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily placebo dentifrice
Number of subjects: 38
Study 25166761 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily fluoride dentifrice
Number of subjects: 38
Study 25166761 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily fluoride dentifrice and once-daily fluoride mouthrinse
Number of subjects: 38
Study 25166761 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrice-daily fluoride dentifrice
Number of subjects: 38
Study 22211481 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 1202
Study 22211481 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1202
Study 20107897 — intervention group
Group type: EXPERIMENTAL
Intervention: SNAP Girls Connection (GC) intervention
Number of subjects: 80